Work

A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.tps3094

Authors: Kunle Odunsi, Mihaela C. Cristea, Oliver Dorigo, Amir A. Jazaeri, Brian M. Slomovitz, Karen Chagin, Erin Van Winkle, Gabor Kari, Malini Iyengar, Elliot Norry, Arundathy N. Bartlett-Pandite, Rafael G. Amado

Institutions: Roswell Park Comprehensive Cancer Center, City Of Hope National Medical Center, City of Hope, Stanford Cancer Institute, The University of Texas MD Anderson Cancer Center, University of Miami

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2892303362

Cites:

Cited by: 10

Related to: 10